Since it is established that CD6 ligands ALCAM and CD318 levels are increased in malignant tumors (19), expression levels of CD6, CD318, and ALCAM were assessed on five human tumor cell lines: MDA-MB-231, MCF-7, NCI-H460, HCT-116, and SKOV-3. This evidence concerns the gene CD6 and cancer.